OncoMatch/Clinical Trials/NCT06412198
A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations
Is NCT06412198 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Cetuximab and Cemiplimab for metastatic colorectal cancer.
Treatment: Cetuximab · Cemiplimab · Adagrasib — To learn if the drug combination of adagrasib, cetuximab, and cemiplimab can help to control metastatic CRC with KRAS G12C mutations.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Biomarker criteria
Required: KRAS G12C mutation
KRASG12C mutation
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: chemotherapy — metastatic
Participants must have received at least one prior line of chemotherapy for metastatic disease with progression on treatment or intolerance to therapy.
Cannot have received: anti-PD-1 therapy
Prior PD1 or CTLA4 inhibition therapy
Cannot have received: anti-CTLA-4 therapy
Prior PD1 or CTLA4 inhibition therapy
Cannot have received: KRAS inhibitor
Prior KRASG12C inhibition therapy
Lab requirements
Blood counts
Absolute neutrophil count ≥ 1,000/mm3; Platelet count ≥ 100,000/mm3; Hemoglobin ≥ 9 g/dL, in the absence of transfusions for at least 2 weeks
Kidney function
Calculated creatinine clearance (Cockcroft-Gault) ≥ 60mL/min at screening
Liver function
Total bilirubin ≤ 1.5x ULN (if associated with Gilbert's disease or UGT1A1*28 homozygosity, ≤ 3x ULN); AST and ALT ≤ 3.0x ULN (if associated with liver metastases ≤5x ULN)
Laboratory values within the screening period: Absolute neutrophil count ≥ 1,000/mm3; Platelet count ≥ 100,000/mm3; Hemoglobin ≥ 9 g/dL, in the absence of transfusions for at least 2 weeks; Total bilirubin ≤ 1.5x ULN (if associated with Gilbert's disease or UGT1A1*28 homozygosity, ≤ 3x ULN); AST and ALT ≤ 3.0x ULN (if associated with liver metastases ≤5x ULN); Calculated creatinine clearance (Cockcroft-Gault) ≥ 60mL/min at screening
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Massachusetts General Hospital Cancer Center · Boston, Massachusetts
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify